TP53 and cancer: EMT‐TFs have been shown to modulate the p53 pathway in cancer cells: a Snail1/HDAC1/p53 trimolecular complex deacetylates active p53 and promotes its proteasomal degradation (Ni et al., 2016), and a Twist1/p53 complex destabilizes the oncosuppressive protein by altering specific post‐translational modifications (Piccinin et al., 2012).